Navigation Links
Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent
Date:5/11/2009

Authors identify important differences between drug-eluting stent brands

NATICK, Mass., May 11 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an article in the current edition of the Journal of American College of Cardiology (JACC) reviewing data on more than 19,000 patients from the Swedish national registry who were evaluated for restenosis, or the re-narrowing of arteries after percutaneous coronary intervention (PCI). The article reported that patients who received a TAXUS(R) Liberte(R) Paclitaxel-Eluting Stent had numerically lower incidences of repeat procedures to treat restenosis at two years as compared to patients treated with 'olimus-based drug-eluting stents (DES), including Cordis' Cypher(R) Stent and Medtronic's Endeavor(R) Stent. In the patients with diabetes, the TAXUS Liberte Stent demonstrated a statistically significant lower restenosis rate compared to the Endeavor Stent, which had more than two times the risk of repeat procedures.

The Swedish Coronary Angiography and Angioplasty Registry holds data on all patients undergoing PCI in Sweden. The objective of this independent study was to evaluate restenosis rates of drug-eluting stents in patients with and without diabetes in a real-world setting. The JACC article reported that both the TAXUS Liberte Stent and Boston Scientific's first-generation DES -- the TAXUS(R) Express(R) Stent -- were the only stents in the study showing no increased risk of restenosis for patients with diabetes as compared to those without diabetes. Both the Cypher Stent and Endeavor Stent showed significant increased risk of restenosis in patients with diabetes. In addition, the study showed that the TAXUS Liberte Stent had an approximately 23 percent lower restenosis rate at two years compared to the prior-
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
2. Spotlight on Rosacea Advance - May Issue of Journal of Drugs in Dermatology Features Pyratine XR(TM) Clinical Study
3. American Lung Association Study to be Published in the New England Journal of Medicine Finds Prescription Heartburn Medication Does Not Control Asthma Symptoms as Previously Thought
4. Landmark Study in The New England Journal of Medicine Shows HPV Testing Significantly Reduces Deaths from Cervical Cancer, Compared to other Methods Including Pap
5. New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation
6. New England Journal of Medicine Publishes Results from Boston Scientifics Landmark SYNTAX(TM) Trial
7. New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation
8. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
9. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
10. Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa
11. Diamyd(R) Study Published in Prestigious New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 2AdEx Media, Inc. Signs Agreement with Medical Alarm Concepts 3Nurses Need to be Included in Health Care Debate according to Professional Nursing Organization 58661 1Nurses Need to be Included in Health Care Debate according to Professional Nursing Organization 58661 2Nurses Need to be Included in Health Care Debate according to Professional Nursing Organization 58661 3ShopAtHome com Helps Shoppers Save Money and Support Breast Cancer Research 58658 1ShopAtHome com Helps Shoppers Save Money and Support Breast Cancer Research 58658 2IBM CEO FDA Commissioner and Top Leaders at Cleveland Clinics Medical Innovation Summit 58655 1IBM CEO FDA Commissioner and Top Leaders at Cleveland Clinics Medical Innovation Summit 58655 2